Isolation, Structure Elucidation and Activity of an Unknown Impurity of Amphotericin B
暂无分享,去创建一个
[1] Hu Chang-qin,et al. RP-HPLC determination of amphotericin B and its liposome , 2006 .
[2] Dai Bi-tao. Liposomal amphotericin B for the treatment of 6 fungal pneumonia children with leukemia , 2006 .
[3] J. Sierra,et al. Low‐dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial , 2004, European journal of haematology.
[4] A. McLachlan,et al. Amphotericin B in Children with Malignant Disease: a Comparison of the Toxicities and Pharmacokinetics of Amphotericin B Administered in Dextrose versus Lipid Emulsion , 1999, Antimicrobial Agents and Chemotherapy.
[5] A. Ganser,et al. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study , 1998, BMJ.
[6] L. Frankel,et al. Treatment of systemic fungal infections with liposomal amphotericin B. , 1989, Archives of internal medicine.
[7] A. Aszalos,et al. Quantitation of amphotericins by reverse-phase high-performance liquid chromatography. , 1984, Journal of pharmaceutical sciences.
[8] P. Sidebottom,et al. The proton magnetic resonance spectrum of amphotericin B , 1981 .
[9] S. Feldman,et al. Toxicity of amphotericin b in children with cancer. , 1979, American journal of diseases of children.
[10] C. Schaffner,et al. POLYENE MACROLIDE DERIVATIVES. I , 1972 .
[11] C. Schaffner,et al. Structure and absolute configuration of the polyene macrolide antibiotic amphotericin B , 1970 .